"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Pavulon Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Pavulon (pancuronium bromide) Injection is a neuromuscular blocking agent used to provide skeletal muscle relaxation during tracheal intubation and surgery. It is available in generic form. Common side effects of Pavulon include skeletal muscle weakness, drooling, rash, bronchospasm, flushing, redness, low blood pressure, and rapid heartbeat.
The recommended dosage range of Pavulon is 0.04 to 0.1 mg/kg of body weight. Pavulon should only be administered under the supervision of experienced clinicians. Succinylcholine, vecuronium, enflurane, isoflurane, neomycin, bacitracin, and colistin may interact with Pavulon. Tell your doctor all medications you take. Exercise caution if you have pulmonary, hepatic, or renal disease while taking Pavulon. If you are pregnant or breastfeeding talk to your doctor and only take Pavulon if the potential benefit outweighs the potential risk.
Our Pavulon (pancuronium bromide) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Pavulon FDA Prescribing Information: Side Effects
The most frequent adverse reaction to nondepolarizing blocking agents as a class consists of an extension of drug's pharmacological action beyond the time period needed. This may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnea.
Inadequate reversal of the neuromuscular blockade is possible with PAVULON® (pancuronium bromide injection) as with all curariform drugs. These adverse experiences are managed by manual or mechanical ventilation until recovery is judged adequate.
Prolonged paralysis and/or skeletal muscle weakness have been reported after long-term use to support mechanical ventilation in the intensive care unit.
See discussion of circulatory effects in CLINICAL PHARMACOLOGY.
Salivation is sometimes noted during very light anesthesia, especially if no anticholinergic premedication is used.
An occasional transient rash is noted accompanying the use of PAVULON® (pancuronium bromide injection) .
Although histamine release is not a characteristic action of PAVULON® (pancuronium bromide injection) , rare hypersensitivity reactions such as bronchospasm, flushing, redness, hypotension, tachycardia, and other reactions possibly mediated by histamine release have been reported.
There have been post-marketing reports of severe allergic reactions (anaphylactic and anaphylactoid reactions) associated with the use of neuromuscular blocking agents, including PAVULON® (pancuronium bromide injection) . These reactions, in some cases, have been life-threatening and fatal. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency (see WARNINGS AND PRECAUTIONS).
Read the entire FDA prescribing information for Pavulon (Pancuronium Bromide Injection) »
Additional Pavulon Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.